About Haley Chartres

This author has yet to write their bio.
Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 172 entries.

Entries by Haley Chartres

Botanix Pharmaceuticals signs exclusive agreement with leading telehealth provider UpScriptHealth®

October 24, 2023 in , , , /by

Botanix Pharmaceuticals (ASX:BOT) has signed an exclusive agreement with UpScriptHealth® to provide the digital platform and telehealth services for the commercial launch of Sofdra™ (sofpironium bromide) gel, 15%. The agreement with UpScriptHealth is an important step towards building the commercial infrastructure for the successful launch of Sofdra following approval. UpScriptHealth was the first company to […]

FDA conditionally approves Sofdra™ as a trade name for sofpironium bromide

October 16, 2023 in , , , /by

Botanix (ASX: BOT) announced today that the U.S. Food and Drug Administration (FDA) has conditionally approved a trade name for sofpironium bromide gel, 15%.  Pending final approval by the FDA, the once-daily topical gel for the treatment of primary axillary hyperhidrosis will be known as Sofdra™.  Our team developed trade name options which would satisfy […]

Investor Webinar Replay | 26 September 2023

September 26, 2023 in , , , /by

Botanix (ASX: BOT) has received a communication from FDA in relation to its NDA submission for Sofpironium Bromide gel, 15% (SB) for the treatment of primary axillary hyperhidrosis. Encouragingly, no clinical efficacy, safety or manufacturing issues were raised and no additional clinical studies are required by the FDA to support approval. We will be revising […]

Bioshares Summit

July 24, 2023 in , , /by

Botanix is joining the biotech investment community at the 17th Bioshares Biotech Summit in Hobart this week. This year’s theme is ‘partnering and financing’, and Botanix Executive Director, Matt Callahan, will be sharing insights into the Company’s progress navigating towards FDA approval for Sofpironium Bromide. Click here to review the presentation.

A$12.5 million institutional placement

July 21, 2023 in , , /by

Botanix has announced it has secured firm commitments for A$12.5 million via an institutional placement. Proceeds from this raise will be used to extinguish future milestone and royalty payments linked to Botanix’s lead product, Sofpironium Bromide (SB) – in a move that could save up to $160 million and prime the Company for potential M&A […]

Video | Investor Webinar

June 7, 2023 in , , , /by

Botanix (ASX: BOT) hosted a webinar recently to update investors on the Company’s progress during the FDA review period for its lead product, Sofpironium Bromide. The webinar was hosted by Executive Director, Matt Callahan and Chief Operating Officer, Howie McKibbon. Take a look.

New territory licensed for Sofpironium Bromide with partner Kaken

June 5, 2023 in , /by

Botanix has today announced that our partner Kaken Pharmaceutical Co Ltd, has secured a new sublicense and distribution agreement for Sofpironium Bromide in Korea. The deal with Dong Wha Pharmaceuticals, Korea’s oldest pharmaceutical company, will see the expansion of Sofpironium Bromide into the Korean market. Sofpironium Bromide has been successfully marketed as ECCLOCK® by sublicensee […]

Investor Webinar Invitation

June 2, 2023 in , /by

Botanix (ASX: BOT) is preparing to host an upcoming investor webinar on Wednesday 07/06/23, 10:30am AEST | 8:30am AWST. On this call, you will hear from Executive Director, Matt Callahan and Chief Operating Officer, Howie McKibbon. Together, they will be sharing an update on our progress during the current FDA-review stage for our lead product […]